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D3 receptors represent a major focus of current drug design and development of
therapeutics for dopamine-related pathological states. Their close homology with the D2
receptor subtype makes the development of D3 selective antagonists a challenging task.
In this review, we explore the relevance and therapeutic utility of D3 antagonists or partial
agonists endowed with multireceptor affinity profile in the field of central nervous system
disorders such as schizophrenia and drug abuse. In fact, the peculiar distribution and
low brain abundance of D3 receptors make them a valuable target for the development
of drugs devoid of motor side effects classically elicited by D2 antagonists. Recent
research efforts were devoted to the conception of chemical templates possibly endowed
with a multi-target profile, especially with regards to other G-protein-coupled receptors
(GPCRs). A comprehensive overview of the recent literature in the field is herein provided.
In particular, the evolution of the chemical templates has been tracked, according to
the growing advancements in both the structural information and the refinement of the
key pharmacophoric elements. The receptor/multireceptor affinity and functional profiles
for the examined compounds have been covered, together with their most significant
pharmacological applications.
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INTRODUCTION
By the last midcentury, it was claimed that dopamine (DA) plays a pivotal role as neurotransmitter
in the central nervous system (CNS). Due to its peculiar distribution in the brain DA controls,
by interacting with its receptors, a variety of functions including locomotor activity, learning
(Beninger, 1983), reward (Wise and Rompre, 1989), motivation, emotion, cognition (Nieoullon,
2002; Cools, 2008), food intake (Volkow et al., 2011), and endocrine regulation (Beaulieu and
Gainetdinov, 2011). Later on, the dopaminergic system has been the focus of intense study and
research, following the evidence that dysfunction of the dopaminergic system could be associated
to a number of pathological conditions such as Parkinson’s disease (Brooks, 2000), schizophrenia
(Brisch et al., 2014), drug abuse and dependence (Volkow et al., 2007). The disclosure of specific
sites of action for DA led to the identification of more than one kind of DA receptors in the brain
(Sibley and Monsma, 1992). Originally, the DA receptors were classified into two subtypes, D1
and D2, owning different biochemical and pharmacological properties, and mediating distinct
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physiological functions. Both the D1 and D2 subtypes are G
protein-coupled receptors (GPCRs) where diverse G proteins
(classified in Gs, Gi, and Gq) and effectors are involved in
mediating their effects on different signaling pathways (Beninger,
1983).
Subsequent biochemical studies, while suggesting the
heterogeneity for the originally described D1 and D2 receptors,
revealed the presence of 5 distinct receptor subtypes (Sibley and
Monsma, 1992). These subtypes, based on sequence homology,
were in turn clustered into two subfamilies, the so called D1-like
receptors (D1 and D5) and the D2-like receptors (D2, D3,
and D4). Typically, D1-like receptors are positively coupled to
adenylyl cyclase (AC) and lead to intracellular cyclic 3,5-adenine
monophosphate (cAMP) accumulation and activation of the
protein kinase A (PKA). In contrast, D2-like receptors are
negatively coupled to AC and negatively modulate the activity
of PKA and its effectors (Rangel-Barajas et al., 2015). Over the
past decades, a large number of agonists and antagonists for
both D1-like and D2-like subfamilies have been developed and
characterized (Butini et al., 2016). Although the design of ligands
characterized by overall selectivity for the D1-like vs. the D2-like
receptors is quite an easy task to be achieved, the development
of specific ligands for a single receptor subtype has proven to be
a tough challenge especially within the same receptor subfamily.
Each receptor possesses an extracellular amino terminus and
seven membrane spanning-helices linked by intracellular and
extracellular protein loops. The carboxyl terminus is located
in the intracellular space and may form a further link to the
membrane. Structurally the D1-like receptors have a short third
intracellular loop and a long carboxyl terminal tail, whereas the
D2-like receptors display opposite features showing long third
loops and short carboxyl terminus (Figure 1).
These differences provided the structural basis for the
clustering of these receptors into the two mentioned subfamilies;
moreover, they could also be linked to their functional outcome
and significance and to specific receptor/G protein interaction
potentially exploitable for the development of subtype selective
ligands.
Detailed information about the structure of DA receptors, also
provided by crystallographic studies for D3 subtypes (Chien et al.,
2010), has greatly facilitated, in the last years, the development of
subtype selective ligands.
In this review, we discuss the development of compounds
behaving as D3 receptor antagonists by focusing our attention
on the literature of the last 10 years. Besides a general discussion
on their structure, affinity and functional profile on DA and
other receptor subtypes, we also provide an overview of their
application in the field of DA-related pathological states, with a
particular focus on schizophrenia and drug addiction models.
D3 RECEPTORS AS MEMBERS OF THE
D2-LIKE FAMILY OF DOPAMINE
RECEPTORS
The D2-like receptor family represented by D2, D3, and
D4 receptors exhibits pharmacological properties similar to
those of the originally defined D2 receptor (Missale et al.,
1998). Post-synaptic D2 receptors are present in dopaminergic
projection areas such as the striatum (50%), limbic areas (nucleus
accumbens, olfactory tubercle), hypothalamus and pituitary
gland. D2 receptors are also located pre-synaptically in the
substantia nigra pars compacta, ventral tegmental area and
striatum, where they modulate the release of DA (De Mei et al.,
2009). Activation of the striatal D2 receptor subfamily in rats
results in a behavioral syndrome known as stereotypy (repetitive
sniffing and gnawing, accompanied by hyperactivity). The
repetitive behaviors observed in humans following amphetamine
ingestion may have a similar neurochemical basis. By contrast,
blockade of the striatal D2 receptor subfamily produces marked
increase in muscle rigidity in rats and a Parkinson-like syndrome
in humans. Administration of a D2 antagonist in humans results
in a rapid and large increase in prolactin release from the anterior
pituitary gland, since the physiological DA inhibition of prolactin
release is blocked.
The D3 and D4 subtypes are much less abundant than
the D2 subtype and have different and more restricted tissue
localization. D3 receptors are predominantly located in areas
considered important for psychotic symptoms such as ventral
striatum including nucleus accumbens, thalamus, hippocampus,
and cortex (Hall et al., 1996; Suzuki et al., 1998; Gurevich
and Joyce, 1999). Some D3 receptors are also found in regions
associated with motor function such as the putamen, whereas D4
receptors are found in the frontal cortex, amygdala, mid-brain
and medulla.
Notably, D3 receptors possess a high affinity for DA (420-fold
higher than that of D2 receptors) and, unlike D2 receptors, small
changes in their number or function may lead to dramatic effects
on synaptic transmission, suggesting that D3 receptors could be
critical modulators of normal dopaminergic function and, despite
their localization, also of cognition.
Recently, the resolution of the crystal structure of the
human D3 receptor in complex with eticlopride, a potent
D2/D3 antagonist (Chien et al., 2010) provided essential hints
for rational drug design aiming at the development of D3
selective ligands. The crystal structure, in fact, highlighted useful
structural differences between closely related GPCRs that can be
exploited for drug design. In particular, the structural observation
of the extracellular binding pocket, which may interact with
bitopic or allosteric ligands, shed light on the role of the
extracellular loops as relevant for defining a specific region for
ligand binding not only at the orthosteric site (Brogi et al., 2014).
In the last decade, several evidences pointed out the
dimerization phenomena of GPCRs as a pivotal issue for
modulating their biological function paving the way to the
future development of innovative drugs. In particular, many
GPCRs have been described to form homodimers, heteromers,
or oligomers (Borroto-Escuela et al., 2014). DA receptors are
the most promiscuous proteins able to form dimers among
the rhodopsin-like GPCRs. Dimerization can occur through
their extracellular loops, transmembrane helices and intracellular
loops. The dimers can be stabilized by covalent (disulphide
bonds) or non-covalent (hydrophobic interactions between
transmembrane helices or coiled coil structures) bonds or a
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FIGURE 1 | (A) Alignment between D1 receptor (as an example of D1-like family) and D3 receptor (as an example of D2-like family) as found by PRALINE (http://www.
ibi.vu.nl/programs/pralinewww/), non-conserved residues are highlighted by dark blue background. (B) Snake plot representation of the above-mentioned receptors
with the non-conserved residues in green for D1 receptor and in orange for D3 receptor. Plots were generated by means of GPCRdb web-server (http://gpcrdb.org/).
combination of both. Although their physiological function is not
completely understood yet, receptor dimers or oligomers have
major consequences on ligand binding, activation of signaling
pathways and cellular trafficking. These complexes, showing
properties different from those found for each single monomer,
may modify the action of DA itself and of different agonists
and antagonists (Maggio et al., 2015). Therefore, targeting
specific GPCR dimersmay provide drugs with enhanced potency,
selectivity, and therapeutic index, representing a promising
alternative to conventional drug development approaches for
CNS disorders.
In particular, D3 receptors can form homodimers or
heteromers with D1 or D2 receptors (Agnati et al., 2016).
D1-D3 receptor heterodimers have been described possessing
different D3 receptor-mediated activation levels on D1 receptors,
and this would make interesting to investigate the differences
in the pharmacological profile of various D1 agonists. D1-D3
heteromers represent an important functional unit in the
brain and are considered promising targets for neuropsychiatric
disorders including Parkinson’s disease and drug addiction
(Guitart et al., 2014; Agnati et al., 2016). Additionally,
heterodimerization was also described for D3 receptors with
other GPCRs such as A2A and neurotensin receptors. Recently
heteromultimers were also reported involving D3 or D2 receptors
with adenosine A2A and cannabinoid CB1 receptors (Maggio
et al., 2015).
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PHARMACOLOGICAL IMPLICATIONS OF
D3 ANTAGONISM
D3 receptors have attracted interest as pharmacological targets
since their peculiar anatomical distribution in the limbic areas
suggests that they may play a role in cognitive and emotional
functions. Accordingly, they hold a valuable potential for
the treatment of neurological and psychiatric disorders being
potentially devoid of the classical D2 receptor subtype side effects
(Hackling and Stark, 2002; Luedtkea and Mach, 2003; Joyce and
Millan, 2005; Newman et al., 2005; Kassel et al., 2015). This
hypothesis has prompted many research groups to develop D3
receptor selective ligands. In this context, there is increasingly
strong evidence that D3 receptor antagonists could be effective
antipsychotic agents and could also be involved in behavioral
sensitization, with potential efficacy in the treatment of drug
abuse.
The most considerable number of reports concerns
the development of D3 antagonists for the treatment of
schizophrenia (Joyce and Millan, 2005) and this approach
is substantiated by a series of evidences. It is well known
that the inhibition of D2 receptors, which is essential for
obtaining antipsychotic efficacy, is accompanied by detrimental
effects on motor functions, causes extrapyramidal side effects,
and increases prolactin release. In this frame, DA receptor
antagonists characterized by D3 selectivity (over D2 receptors)
are not expected to elicit such marked side effects (Millan
et al., 2000). This lack of side effects liability is paralleled by the
encouraging evidence that selective blockade of D3 receptors
enhances social interaction and novel object recognition in rats
(Watson et al., 2012). These rodent models efficiently mimic the
negative symptoms of schizophrenia, which are poorly treated by
conventional antipsychotics thus supporting D3 antagonism as a
valuable approach for the treatment of this cluster of symptoms.
Further, D3 receptor antagonists might also improve cognitive
deficits in schizophrenic patients which are also poorly treated by
currently available agents, including clozapine (Meltzer, 2004).
Indeed, blockade of D2 receptors may compromise cognitive
performance, while D3 antagonism was suggested to improve
certain cognitive spheres. This could be due to a modulation of
the cholinergic system, by increasing acetylcholine release at the
prefrontal cortex level, operated by the D3 receptor antagonism
(Millan et al., 2008). In fact, treatment of rats with S33138, a
preferential D3 vs. D2 receptor antagonist, was demonstrated to
provide enhanced efficacy against cognitive dysfunction induced
by several contrasting manipulations (Millan and Brocco,
2008).
Moreover, deficits in the sensorimotor gating, assessed by
the prepulse inhibition (PPI) of the startle reflex, have been
reported in schizophrenia, and might correlate with the positive
symptoms (Meincke et al., 2004). PPI is an operational measure
of sensorimotor gating, reflected as a reduced startle response
when a startling stimulus is preceded by a weaker acoustic
stimulus (Zhang et al., 2007). Current data indicate that although
the disruption of PPI is mediated by D2 receptors, but not D3
or D4 receptor subtypes, selective D3 antagonists can reverse the
PPI-disruptive effects of other substances such as apomorphine.
The selective involvement of the D3 receptors in crucial
neuronal circuits controlling motivational events triggered
the identification of selective D3 receptor antagonism as a
feasible therapeutic strategy against addiction (Heidbreder and
Newman, 2010). This perception was further substantiated by
several evidences highlighting plasticity changes in drug-addicted
subjects, such as the increase in D3 receptor density in cocaine
addicts and metamphetamine polydrug users (Staley and Mash,
1996; Boileau et al., 2012). Cocaine addiction represents a
risk factor for schizophrenia and is likewise associated with
a sensitization of the mesolimbic dopaminergic pathways and
increased DA release in the mesolimbic brain area (Xi et al.,
2004). In analogy with this observation, schizophrenic patients
show a high incidence of abuse of drugs including cocaine.
Craving is a general central trait of addictive disorders. Drug-
seeking behavior can be triggered by drug withdrawal or after a
“priming dose.” Moreover, drug craving can follow the exposure
to stimuli previously associated with consumption of the drug of
abuse (“cue-induced craving”).
Neuroimaging studies in humans link drug-associated visual
cues with DA release in the dorsal striatum and cocaine craving
(Wong et al., 2006; Volkow et al., 2006, 2008). In animals,
cocaine-associated cues sustain cocaine self-administration (Ito
et al., 2004), increase cocaine seeking (Ciccocioppo et al., 2004),
and elevate extracellular DA levels in the nucleus accumbens
(Aragona et al., 2009), dorsal striatum, and amygdala (Carelli
et al., 2003). A more recent study also evidences that cue-
induced incubation of cocaine craving coincides with an increase
of D3 (and not D1 or D2) receptor expression in the nucleus
accumbens and ventral caudate-putamen in rats after prolonged
withdrawal from cocaine self-administration (Conrad et al.,
2010), suggesting a possible role for increased D3 receptor
signaling in incubation of cocaine craving. These evidences
delineate a clear direction of intervention, based on D3 receptors
antagonism or partial agonism, for the treatment of craving and
drug addiction.
D3 RECEPTOR ANTAGONISTS
Based on the interest that D3 receptors raised as an intriguing
therapeutic target for the treatment of different neurological
disorders and drug abuse, many efforts were dedicated in the last
two decades to the development of D3 receptor ligands.
As regards to D3 receptor antagonists, a pharmacophore
model was proposed based on the structure of a series of
antagonists characterized by a different degree of selectivity for
D3 vs. the close homologous D2 receptor subtype (for more
details see Butini et al., 2016). The model consists in an aryl
moiety (Ar1 of Figure 2) linked by a H-bond acceptor function
(an amide) to a spacer of appropriate length (usually four
methylene units) to the basic moiety very frequently represented
by an arylpiperazine system (Hackling and Stark, 2002; Löber
et al., 2011).
Amongst the big variety of structures reported in the literature
of the last two decades, some early ligands, which were claimed as
D3 receptors selective antagonists (or partial agonists) attracted
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particular attention and in our opinion deserve some “historical”
mention: BP897 (1, Figure 3; Pilla et al., 1999; Garcia-Ladona
and Cox, 2003), NGB2904 (2, Figure 3; Yuan et al., 1998; Xi and
Gardner, 2007), SB277011A (3a, Figure 3; Reavill et al., 2000;
Thanos et al., 2005), and FAUC 365 (4, Figure 3; Bettinetti et al.,
2002).
Compound 1 was a potent DA D3 receptor ligand (K i = 0.92
nM), showing a 70-fold selectivity vs. D2 receptors and a
moderate affinity for 5-HT1A receptors, (K i = 84 nM),
adrenergic alpha1 (K i = 60 nM), and alpha2 adrenoceptors (K i
= 83 nM). Although 1 behaved as partial agonist for the D3
receptors, it was not endowed with intrinsic activity and potently
inhibited DA agonist effects in agonist-induced acidification rate
or increase of GTPγS binding. This compound raised a big
interest, since it was demonstrated to reduce cocaine-seeking
behavior in rats (1 mg/kg i.p.) without producing reinforcement
on its own, thus highlighting and endorsing the role D3 receptor
for the treatment of cocaine abuse.
FIGURE 2 | Pharmacophore model for D3 selective ligands.
By substitution of the 2-methoxyphenyl- with the 2,3-
dichlorophenyl- moiety linked to the piperazine nitrogen,
another series of potent and selective D3 ligands was
developed. The representative compound of this series, the
fluorenylcarboxamide-based derivative NGB2409 (2), was
originally described in 1998. It showed a selective D3 antagonism
profile (K i = 0.90 nM), displaying high affinity for this receptor
subtype with greater than 150-fold selectivity over all other
DA receptor subtypes (Yuan et al., 1998). Following studies
highlighted its role in animal models of addiction, by inhibiting
intravenous cocaine self-administration maintained under a
progressive-ratio reinforcement schedule, cocaine- or cocaine
cue–induced reinstatement of cocaine-seeking behavior, and
cocaine- or other addictive drug-enhanced brain stimulation
reward (Xi and Gardner, 2007).
In 2005 compound 3a (SB277011A) was described as a brain-
penetrant, high-affinity, and selective D3 receptor antagonist
(pK i = 7.95) with 100-fold selectivity over the D2 receptor
and over 60 other receptors, enzymes, and ion channels
(Thanos et al., 2005). Notably a structurally related compound,
SB269,652 (3b) able to bind D2 and D3 receptors and behaving
as atypical antagonist was recently reinvestigated in light of
the D3 receptor dimerization. Binding kinetic studies and
crystallographic analysis pointed out that 3b behaves as dual-
steric agent targeting orthosteric and allosteric binding sites
of heteromers. In fact this so called “dual-steric ligand” is
long enough to bridge orthosteric and allosteric binding sites,
providing an exceptional selectivity for D2-D3 dimers, with
relevant clinical implications (Silvano et al., 2010; Maggio et al.,
2015, see also Butini et al., 2016 for further details). Structural
FIGURE 3 | Early identified D3 selective ligands.
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elaboration of the D3 receptor pharmacophore allowed the
identification of the benzothiophene-2-carboxamide FAUC365
(4) which resulted in a complete D3 receptors antagonist profile,
endowed with high affinity (K i = 0.50 nM) and selectivity
(Bettinetti et al., 2002).
ARYLPIPERAZINE-BASED D3 RECEPTOR
INHIBITORS
In the following years, a number of manuscripts describing the
development of arylpiperazine-based compounds appeared in
the literature.
Amongst the variety of retrieved compounds, KKHA-761
(5, Figure 4) was interesting since it was described as a
potent D3 receptor antagonist with high 5-HT1A receptor
affinity, exhibiting antipsychotic properties in animal models of
schizophrenia (Park et al., 2005). In particular, it behaved as
a D2-like receptor antagonist with a high affinity for human
D3 receptor (K i = 3.85 nM) with 70-fold selectivity over the
D2 receptor (K i = 270 nM) and it also displayed high affinity
for human 5-HT1A receptor (K i = 6.4 nM). Compound 5
was characterized by a pharmacological profile tracing out that
of atypical antipsychotics, like clozapine. In fact 5, among
other behavioral effects indicative of antipsychotic activity, could
significantly reverse the apomorphine-induced disruption of PPI
in mice thus suggesting a therapeutic potential for the treatment
of anxiety, psychotic depression, and other related disorders
(Park et al., 2005).
In this context, also Campiani et al. reported the synthesis
of highly selective D3 receptor ligands (compounds 6a-c and
7a,b, Figure 4) characterized by antagonist or partial agonist
activity at D3 receptors and with a D3 vs. D2 selectivity
higher than 100-fold combined with 5-HT1A and 5-HT2A
receptor occupancy. This represented a novel paradigm for
the development of innovative and effective antipsychotics. In
particular, compound 6c emerged as interesting hit displaying
high affinity for D3, 5-HT1A and 5-HT2A receptors, coupled
with a low affinity for D2 receptors (to minimize extrapyramidal
side liabilities), 5-HT2C receptors (to decrease the risk of obesity
under chronic treatment), and for ether-a-go-go related gene
(hERG) channels (to reduce cardiotoxicity). Moreover, c-fos
expression in mesocorticolimbic areas, confirmed the atypical
antipsychotic profile of 6c in vivo, flanked by the absence of
FIGURE 4 | Arylpiperazine-based derivatives 5-10.
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catalepsy at antipsychotic dose (Campiani et al., 2003; Butini
et al., 2009).
In 2009 Weber and colleagues demonstrated that some
derivatives such as WC-44 (8, Figure 4), initially identified as
a selective D3 receptor agonist (K i = 2.4 ± 0.5 nM), showed
instead functional D3 receptor antagonism and possibly an
innovative antipsychotic profile. Indeed, in apomorfine- and
pramipexole-induced PPI deficits studies, it did not significantly
oppose to PPI deficits in apomorfine experiments while it
opposed to that of pramipexole-induced analysis, thus suggesting
a novel antipsychotic profile for 8 linked to functional D3
receptor antagonism (Weber et al., 2009).
To the same end, Newman and co-workers prepared some
2-methoxyphenylpiperazine compounds bearing a quinoline
heterocycle and explored whether the position of the quinoline
nitrogen (2-, 3-, or 7-position) had any effect on binding
affinity and/or selectivity. Also they inserted a 3-hydroxy
substituent in the linker between the arylamide terminus and
the 4-phenylpiperazine moiety. The best results, in terms of
D3 affinity and selectivity, were obtained with derivatives
FIGURE 5 | Arylpiperazine-based derivatives 11-15.
FIGURE 6 | Pyrimidinylpiperazine-based compounds 16–19.
Frontiers in Neuroscience | www.frontiersin.org 7 October 2016 | Volume 10 | Article 451
Maramai et al. D3 Receptor Antagonists
FIGURE 7 | Deconstruction studies performed on D3 receptor ligands 6a and 20.
9a,b (Figure 4), even though the hydroxy group at the 3-
position brought a small drop of activity (K i = 2.51 nM and
33.8 nM, respectively). The connection point of the amide
functionality to the quinoline ring did not appear to strongly
influence binding affinity and/or selectivity at D3 receptors,
as well as the presence of an electron-withdrawing group on
the quinoline ring. These compounds resulted in moderately
potent antagonists, expressing weak partial agonist profiles at
higher concentrations. This report further confirmed that the
quinoline system represents a good scaffold for the development
of D3 antagonists in terms of selectivity over D2 receptors.
In fact, also derivatives 10a,b (Figure 4), in line with their 2-
methoxyphenylpiperazine counterparts 9a,b, behaved as potent
and selective D3 antagonists displaying ability in reducing heroin
self-administration. The same effect was not encountered in D3
knockout mice thus clearly demonstrating the involvement of
D3 receptors (Boateng et al., 2015). The data regarding intrinsic
affinity described in this paper essentially match with previous
findings by Campiani et al. (2003), described by the development
of compounds 7a,b which were tested in cocaine craving.
Substantial elaboration of the pharmacophore model of
Figure 2 allowed the identification of RGH-188 (11, Figure 5),
also known as cariprazine, a compound demonstrating
subnanomolar affinity for D3 receptors and nanomolar affinity
for D2 receptors (Kiss et al., 2010). This compound was
developed in a medicinal chemistry approach (Agai-Csongor
et al., 2012) aiming at the optimization of an impurity originally
isolated during the scale-up process of a pyridylsulfonamide-
based lead which behaved as D3/D2 antagonist. Cariprazine, was
approved in 2015 in the USA for the treatment of schizophrenia
and bipolar disorders under the trade name of Vraylar. The
FIGURE 8 | Schematic representation of the flexible
arylpiperazinecarboxamides binding the OBS and SBP of the D3
receptor.
structural innovation that this compound brought to the
pharmacophoric model of Figure 2 resided in the absence of one
aromatic moiety which was efficiently replaced by a hydrophobic
cyclohexyl ring system. Also the lack of the amide function
connected to Ar1 of Figure 2 was replaced by an ureido moiety
on the west end of the molecule. Cariprazine was demonstrated
to have antagonist–partial agonist activity at both D2 and D3
receptors and animal studies highlighted its efficacy for the
treatment of schizophrenia and bipolar mania (Kiss et al., 2010).
Further studies demonstrated that compound 11 was able to
parallel the effect of the atypical antipsychotic aripiprazole in
reducing the rewarding effect of cocaine and attenuated relapse
to cocaine seeking (Román et al., 2013). In adult male rats, 11
dose-dependently reversed delay-induced impairment in novel
object recognition. Further, acute administration (0.1 and 0.3
mg/kg orally) to animal models of phencyclidine-induced social
isolation (in neonatal rats) reduced the symptoms and induced
locomotor hyperactivity (Watson et al., 2016). Seminal clinical
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trials allowed to confirm the therapeutic potential of 11 in
patients with acute exacerbation of schizophrenia (Durgam et al.,
2015, 2016). Efficacy, safety, and tolerability of 11 were assessed
in patients with acute mania associated with bipolar I disorders
(Calabrese et al., 2015).
Notably, some studies also evidenced the efficacy of the
compound in the treatment of the negative symptoms of
schizophrenia (Debelle et al., 2015). The clinical efficacy of this
D3 preferring ligand further confirms the role of D3 receptors
in the management of the symptoms of schizophrenia (Citrome,
2016). Learning from 11 that the aromatic group such as Ar1
of Figure 2 is not mandatory for attaining potent and selective
D3 antagonism, Capet and colleagues synthesized a series of
aliphatic amides and some ureidic analogs. Structure-activity
relationship studies on this set of compounds showed that, as
far as these products were lipophilic enough, they behaved as
potent ligands (partial agonists) for human D3 receptors and the
cyclohexyl amide analog 12 (Figure 5) was characterized as the
best performing compound of the series (Capet et al., 2016).
One of the major drawbacks shared by many centrally active
molecules, particularly those active at monoaminergic receptors,
is the detection of high affinity at hERG potassium channels.
Channel inhibition is associated to drug-induced torsades de
pointes arrhythmia which is a major safety concern in the
process of drug design and development. In fact hERG affinity
is hard to be reduced in a drug design approach while retaining
high receptor affinity. Unfortunately, compound 12 potently
interacted with the hERG channels (82% inhibition of dofetilide
binding when tested at 1 µM; Capet et al., 2016).
In a recent report describing the development of a series of
arylpiperazines as potential atypical antipsychotics endowed with
a multireceptor affinity profile, Brindisi and colleagues provided
evidence that for compound 13 (Figure 5) they could achieve to
lower hERG affinity up to 10 µM while retaining subnanomolar
affinity for D3 receptors and nanomolar potency at 5-HT1A and
5-HT2A receptors [K i (D3) = 0.6 nM, K i (5-HT1A) = 99 nM,
K i (5-HT2A) = 66 nM; Brindisi et al., 2014]. This analog is
endowed with a unique in vitro multireceptor pharmacological
profile characterized by pronounced selectivity over the D2 (K i
(D2) > 1000 nM) and 5-HT2C receptors (K i (5- HT2C) > 1000
nM). To further complement the significant efficacy profile
of compound 13, assessed in behavioral tests predictive of
antipsychotic efficacy (e.g., MK801-induced hyperactivity and
phencyclidine–induced PPI in mice) a promising therapeutic
window was also ascertained by the absence of catalepsy at the
antipsychotic effective dose and also in passive avoidance tests.
Lack of cardiotoxicity in isolated Langendorff heart was also
verified for this compound (Brindisi et al., 2014).
Newman and colleagues identified the first enantioselective
D3 antagonists PG648 (R-14, Figure 5), bearing an indole
system as suitable substructure for D3 ligand affinity, in which
enantioselectivity was more pronounced at D3 than at D2
receptors and could represent a valuable characteristic for
D3 receptor selectivity (K i = 1.12 nM, 400-fold selective
FIGURE 9 | Arylpiperazine-based D3 “dimeric” and bitopic ligands 28 and 29.
FIGURE 10 | Tranylcypromine (30) and Tranylcypromine-based analog 31.
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FIGURE 11 | Compounds 32 and 33 and structurally related triazole-based D3 antagonists 34–36.
D2/D3). Interestingly, this compound also exhibited balanced
physico-chemical characteristics, useful for an appropriate
in vivo exploration and determination of intrinsic activity
at D3 receptors in animal models of addiction and other
neuropsychiatric disorders (Newman et al., 2009).
The 2-pyridylphenyl analog 15 (Figure 5) with a K i =
0.7 nM for D3 receptors and a D2/D3 selectivity ratio of
133, originally described in 2005 and after evaluation in
animal models of cocaine abuse, served as an important
pharmacological tool for highlighting the contribution of D3
receptors in drug reinforcement in vivo (Grundt et al., 2005).
A more recent investigation of the same compound reported
its useful application on methamphetamine self-administration,
methamphetamine-associated cue-induced reinstatement
of drug seeking and methamphetamine-enhanced brain
stimulation reward, thus highlighting the possible role of D3
antagonists also in the treatment of methamphetamine addiction
(Higley et al., 2011).
A series of interesting compounds displayed a tert-butyl-
trifluoromethylpyrimidine moiety connected to the piperazine.
An early lead of this series was compound ABT-925 (16,
Figure 6), which showed high affinity for the human D3 receptor
(K i = 2.9 nM), with at least 100-fold selectivity over the
human D2 and other receptors, enzymes, and ion channels.
This compound was a potent antagonist of D3 receptors, it
could easily cross the blood–brain barrier and exerted efficacy
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in different animal models predictive of antipsychotic activity
without inducing catalepsy or raising plasma prolactin levels
(Geneste et al., 2006). The same report also described the
methylpyridin-2-one analog 17 (Figure 6) which retained a good
activity and selectivity for D3 vs. D2 receptors (K i = 0.8 nM,
with >80-fold selectivity vs. D2 receptors). However, within this
class of compounds the best performances were achieved with
the disclosure of SR21502 (18, Figure 6) which displayed a K i
= 4.2 nM at the D3 receptors with >120-fold of selectivity over
the D2 receptors. Although, 18 behaved as weak partial agonist at
the D3 receptors, in the agonist-stimulated mitogenesis assay, it
behaved as an antagonist at D3 receptors (Ananthan et al., 2014).
Compound 18 was recently employed as a pharmacological
tool for evaluating its in vivo activity against cocaine reward
and cocaine-seeking behaviors. Experimental data demonstrated
efficacy of 18 against these behaviors which was not accompanied
by effect on food reward or spontaneous locomotor activity (Galaj
et al., 2014; Hachimine et al., 2014).
Among the pyrimidinylpiperazine derivatives, compound 19
(Figure 6) bearing a phenylcyclohexanecarboxamide moiety was
recently characterized as a potent D3 vs. D2 receptors antagonist
(K i = 9.4 nM) with >150-fold selectivity over D2 receptors, thus
fostering further investigation for these analogs as antipsychotics
or in models of drug addiction (Ananthan et al., 2014).
In order to elucidate the structural features responsible both
for D3 vs. D2 receptors efficacy and selectivity, in 2012 Newman
and co-workers reported a deconstruction study on substituted-
4-phenylpiperazines 6a and 20 (Figure 7; Newman et al., 2012).
D3 receptors feature an orthosteric binding site (OBS),
which binds DA, that is very similar to that of D2 receptors,
and this represents a major issue in the development of
D3 selective ligands. The Authors evidenced how selectivity
could be managed by means of divergent interactions within
a second binding pocket (SBP) which is distinct from the
OBS. Notably, they also indicated that, the binding mode at
SBP is highly influenced by that observed at the OBS. For
reaching this conclusion the Authors studied the binding mode
(by computational analysis) and affinity profile of a series of
fragments (21-27, Figure 7) of compounds 6a (Campiani et al.,
2003) and 20 (Chu et al., 2005). They identified a primary
pharmacophore element (the arylpiperazine moiety, Figure 8)
which should bind the OBS, and a secondary pharmacophore
element (the arylamide moiety, Figure 8) which should bind the
SBP. Interestingly, these aspects could be translated to other
GPCRs and, as a general “rule,” it could be assumed that the SBP
can be targeted by bitopic or allosteric ligands.
An earlier report by Butini and co-workers described
the development of bishomo- or hetero-arylpiperazines (28,
Figure 9) as flexible ligands for specific occupancy of D3, 5-
HT1A, and 5-HT2A receptors. These compounds represent a
different class of ligands when compared to the general structure
of the proposed pharmacophoric model (see Figure 2; Butini
et al., 2010). However, the same compounds may also comply
with the above mentioned study of Newman and coworkers,
but the nature of these homodimeric or heterodimeric ligands
implies that both the primary pharmacophore element and the
secondary pharmacophore element are arylpiperazines indeed.
FIGURE 12 | Representation of the novel pharmacophoric model
proposed by Micheli et al. (Bonanomi et al., 2010; Micheli et al., 2010b),
with compound 35 and its features.
The same consideration may be true for bitopic ligands such as
29 (Figure 9) developed by Huber and colleagues in 2009 (Huber
et al., 2009).
A further structural modification characterizes the
new compound 31 (Figure 10), developed by Chen and
co-workers, with marked differences from the classical
arylpiperazine selective ligands. However, 31 still perfectly
fitted the arlypiperazine–based pharmacophore of Figure 2.
Compound 31 was a potent and selective D3 receptor antagonist
based upon tranylcypromine (30, Figure 10) which effectively
replaced the arylpiperazine moiety (Chen et al., 2014).
Although 30 had a low affinity for rat D3 receptors (K i =
12.8 µM), derivative 31 showed K i values of 2.7 and 2.8 nM at
the rat and human D3 receptors, respectively, and displayed a
high selectivity over the rat and human D2 receptors (>10,000-
fold and 223-fold respectively). These features of compound
31 complemented by a good pharmacokinetic profile and brain
permeability made it a promising candidate for the potential
treatment of drug abuse.
1,2,4-TRIAZOLE-BASED D3 RECEPTOR
LIGANDS
The arylpiperazine system proved to be an exceptionally valuable
option for the design and development of selective D3 ligands,
endowing the new compounds with different in vitro outcomes
as both partial agonists and antagonists. However, in the last
years, alternative scaffolds emerged such as 1,2,4-triazole-based
derivatives which have been characterized as optimal alternative
to the more conventional arylpiperazine-based pharmacophore
of Figure 2. These studies led to the discovery of interesting
structures potentially useful for the treatment of schizophrenia
and related disorders.
An early series of triazole-based D3 antagonists was developed
by drawing inspiration from the structure of compound
32 (Figure 11), a tetrahydro-1H-3-benzazepine which was
described as a potent and selective D3 receptors antagonist with
high oral bioavailability and blood-brain barrier permeability
(Macdonald et al., 2003).
Frontiers in Neuroscience | www.frontiersin.org 11 October 2016 | Volume 10 | Article 451
Maramai et al. D3 Receptor Antagonists
FIGURE 13 | Morpholino/triazole analogs 37a–c.
FIGURE 14 | General structure of octahydropyrrolo[2,3-b]pyrrole-based D3 antagonists 38 and 39.
Also compound ST-198 (33, Figure 11), developed by Bézard
and colleagues, bearing a tetrahydroisoquinoline moiety, resulted
in a selective D3 antagonist over a wide panel of receptors (Bézard
et al., 2003).
Subsequently, with the development of compound 34
(Figure 11) Micheli and co-workers highlighted that the
thiotriazole scaffold coupled to a pyrazolyl moiety represented
a promising combination for the design of D3 antagonists. In
particular, 34 (Figure 11) showed good oral bioavailability and
brain penetration associated with high potency and selectivity for
D3 receptors in vitro (functional pK i obtained from the GTPγS
functional assay = 8.8). An in depth in vivo characterization of
34 showed its ability to prevent nicotine-induced conditioned
place preference behavior in rats and to reduce alcohol self-
administration. Moreover, it retained a low interaction with
hERG channels and no QTc interval prolongation was observed
in electrocardiograms, thus indicating a favorable potential for
34 to turn into an optimal candidate for the treatment of drug
addiction, psychosis, and schizophrenia (Micheli et al., 2007).
More recently Micheli and collaborators reported an ample
series of 1,2,4-triazolyl azabicyclo[3.1.0]hexanes as selective
D3 receptors antagonists in which the oxazolyl derivative 35
(Figure 11) showed good affinity and selectivity coupled with
optimal pharmacokinetic properties (Bonanomi et al., 2010;
Micheli et al., 2010b). Successively, compound 35 was used
in studies regarding food cues in a human addict population,
where it showed a lack of attentional bias toward food if
compared with the placebo (Nathan et al., 2012). These data
provided additional support that antagonism for D3 receptors
may attenuate attentional processing of salient or rewarding
cues. On the basis of the abovementioned results, the same
Authors proposed a new pharmacophore model useful for the
rationalization of the activity and selectivity profiles of this new
series of compounds (Figure 12).
This also allowed the identification of alternative
scaffolds to the azabicyclo[3.1.0]hexane, by the analysis of
differently decorated amines that nicely fitted in the proposed
pharmacophore model and prompted the synthesis of derivatives
(36a-g, Figure 11; Micheli et al., 2010a).
Very recently, Micheli and colleagues reported the
development of D3 ligands by means of a “scaffold hopping”
strategy that resulted in the identification of a variety of original
basic moieties and, more specifically, a morpholine system, to be
spaced from the thiotriazole by a three-methylene tether (Micheli
et al., 2016b). Derivative 37a (Figure 13), one of the most active
and selective D3 ligand of this interesting series, displayed a
very high D3/D2 selectivity (800-fold) accompanied by a 60-fold
selectivity vs. the hERG channel. Structure-activity relationship
studies demonstrated that shift of the position of pyridine
nitrogen reduced the affinity at D3 receptors, while its removal
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(benzamide 37b, Figure 13) still allowed to maintain high
D3 receptors affinity and D3/D2 selectivity accompanied by a
notable 150-fold selectivity vs. the hERG channel. The compound
bearing the oxazole moiety (37c, Figure 13) surprisingly showed
increased affinity at the D3 receptors with 300-fold selectivity vs.
D2 and 200-fold vs. hERG channel. These compounds, bearing
a chiral center at the morpholino system level, were described
and tested as racemates, although some of the pure enantiomers
were tested showing different selectivity profile, highlighting a
stereoselective interaction with DA receptors.
Another interesting and very wide series of ligands was
reported by the same Authors (Micheli et al., 2016a) bearing
an octahydropyrrolo[2,3-b]pyrrole scaffold characterized by high
affinity and selectivity at D3 receptors (general structures 38
and 39, Figure 14). Substituents at R1 position were -OMe, 2,3-
dichloro, -CF3 groups or fluorine atoms in general structure
38, while R2, when different from the oxazole ring, could be a
pyridine, pyrazine, pyrimidine, or pyridazine moiety, combined
with the above listed R1 substituents (general structure 39). Many
of these derivatives proved to have ideal in vitro pharmacokinetic
developability and, for some selected analogs, a large selectivity
panel assessment campaign was performed including hERG
channels.
CONCLUSION
In this review, an overview of the literature of the last
10 years in the field of D3 antagonists was provided. The
careful examination and clustering of the most significant
compounds taken into consideration allowed delivering an
overall picture of their structural variability. At the same time,
the proposed analysis highlighted the substantial structural
commonalities, despite the efforts of different research groups for
providing pharmacophore refinements aiming at the discovery
of innovative scaffolds for attaining high D3 receptor affinity
and selectivity over the D2 receptors. The description of
the pharmacodynamic (multi)receptor affinity profile and the
most significant pharmacological applications for the examined
compounds in the field of DA-related brain disorders were also
covered, in order to provide clear-cut hints for their therapeutic
potential.
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